Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07645300 · ClinicalTrials.gov registry record · Phase 2
LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial
A Phase 2 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT07645300: Clinical Trial Phase 2 study, sponsored by VA Office of Research and Development.
NCT07645300 is a Phase 2 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 160 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07645300, a Phase 2 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.
Primary Outcome
phase 2A: the primary endpoint will be assessed by change from baseline to 6 weeks and 12 weeks in systolic AOBP for the combination group compared to placebo.
Interventions
- DRUG phase 2A Chlorthalidone
- DRUG phase 2A Spironolactone
- DRUG phase 2A Chlorthalidone + Spironolactone
- DRUG phase 2B Chlorthalidone LD + Spironolactone LD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2032-06-30 |
| Phase | Phase 2 |
What is known before NCT07645300 opens enrollment
NCT07645300 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 4 interventions - of which phase 2A Chlorthalidone is the first listed.
NCT07645300 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07645300 about?
NCT07645300 is a clinical study titled "LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial". The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high...
What is the current status of trial NCT07645300?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2026-10-01. Estimated completion is 2032-06-30.
What interventions are being tested in trial NCT07645300?
The interventions under investigation include: phase 2A Chlorthalidone (DRUG), phase 2A Spironolactone (DRUG), phase 2A Chlorthalidone + Spironolactone (DRUG), phase 2B Chlorthalidone LD + Spironolactone LD (DRUG).
Who is sponsoring clinical trial NCT07645300?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07645300's enrollment target sits among peer trials
160 422nd of 2000 higher than 1,559 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI